Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A
Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A
TORONTO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021 and Management Discussion & Analysis ("MD&A") for the three months ended September 30, 2021 will be filed on November 29, 2021.
多倫多，2021年11月26日(環球通訊社)Syenence Group Inc.(CSE：PSYG|OTCQB：PSYGF) ("精神病學“或”公司)，一家專注於精神健康和健康方面的天然迷幻劑的生命科學生物技術公司宣佈，截至2021年9月30日的6個月的未經審計的綜合中期財務報表和截至2021年9月30日的3個月的管理討論和分析(“MD&A”)將於2021年11月29日提交。
As a result of a continuous disclosure review conducted by Staff of the Ontario Securities Commission, the Company has included enhanced disclosure in its MD&A relating to, among other things, liquidity and cash resources, discussion of operations, its projects, expenditures made, and the timing and costs anticipated to advance the Company's projects to the next stage. The Company has also enhanced its disclosure regarding the regulatory framework relating to psychedelic substances in each jurisdiction where the Company operates.
由於安大略省證券委員會的工作人員進行了持續的信息披露審查，該公司在其MD&A中增加了關於流動性和現金資源、運營討論、項目、支出以及預期將公司項目推進到下一階段的時間和成本的信息披露。該公司還加強了其在公司運營的每個司法管轄區有關迷幻物質監管框架的披露。
The Company has also filed its management information circular dated November 18, 2021 which includes the executive compensation disclosure required by Form 51-102F6V, Statement of Executive Compensation, which was not previously filed.
公司還提交了日期為2021年11月18日的管理信息通告，其中包括51-102F6V表格要求的高管薪酬披露。《高管薪酬説明書》這是之前沒有提交的。
ABOUT PSYENCE GROUP: www.psyence.com
關於精神病組：Www.psyence.com
Psyence is a public life science biotechnology company listed on the Canadian Securities Exchange and (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Mental ence是一家在加拿大證券交易所上市的公共生命科學生物技術公司，(CSE：PSYG)並在OTCQB上引用(OTCQB：PSYGF)，重點放在天然迷幻藥上。在姑息治療的背景下，精神病學與天然裸蓋菇素產品一起治療心理創傷及其精神健康後果。
Our name "Psyence" combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.
我們的名字“精神病學”結合了迷幻劑和科學確認我們致力於生產通過循證研究開發的迷幻藥物。
Informed by nature and guided by science, we built and operate one of the world's first federally licensed commercial psilocybin mushroom cultivation and production facilities.
我們以自然為基礎，以科學為指導，建成並運營了世界上首批獲得聯邦政府許可的商業裸蓋菇菇種植和生產設施之一。
Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development. We work to develop advanced natural psilocybin products for clinical research and development. We have entered into a long term joint venture to launch mushroom-based mental wellness focused nutraceutical products, the GOODMIND™ collection, to support improved focus, calm, and sleep.
我們的團隊帶來了商業和科學方面的國際經驗，幷包括真菌學、神經學、姑息治療和藥物開發方面的專家。我們致力於開發先進的天然裸蓋菇素產品，用於臨牀研究和開發。我們已經成立了一家長期的合資企業，推出以蘑菇為基礎的精神健康保健產品，GOODMIND™系列，以支持改善注意力、平靜和睡眠。
Our key divisions, Psyence Production, Psyence Therapeutics, and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Jamaica, South Africa and a presence in the United States and Australia.
我們的主要部門--精神病學生產、精神病學治療和精神病學功能--在加拿大、英國、牙買加、南非開展業務，並在美國和澳大利亞開展業務，為國際合作奠定了基礎。
Contact Information:
Lisa-Marie Iannitelli, Investor Relations
Email: ir@psyence.com
聯繫信息:
麗莎-瑪麗·伊安尼特利(Lisa-Marie Iannitelli)，投資者關係部
電子郵件：ir@mental ence.com
Media Inquiries: media@psyence.com
General Information: info@psyence.com
媒體查詢：media@mental ence.com
一般信息：info@ological ence.com
FORWARD LOOKING STATEMENTS:
Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively "the Company") are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations.
前瞻性陳述：
本新聞稿中的某些陳述涉及Mental Group Inc及其子公司(統稱為“《公司》“)是前瞻性陳述，具有前瞻性。前瞻性陳述不是基於歷史事實，而是基於對未來事件的當前預期和預測，因此會受到風險和不確定因素的影響，這些風險和不確定性可能會導致實際結果與前瞻性陳述明示或暗示的未來結果大不相同。這些陳述通常可以通過使用“可能”、“應該”、“可能”、“打算”、“估計”、“計劃”、“預期”、“預期”、“相信”或“繼續”等前瞻性詞彙或其否定或類似變體來識別。
There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
有許多風險和不確定因素可能導致實際結果以及公司的計劃和目標與前瞻性信息中所表達的大不相同。實際結果和未來事件可能與此類信息中預期的大不相同。這些和所有隨後的書面和口頭前瞻性信息都是基於管理層對其作出日期的估計和意見，並明確地完全符合本通知的要求。除非法律另有要求，否則公司不打算更新這些前瞻性陳述。
The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.
本公司不對本公司建議的產品提出任何醫療、治療或健康福利要求。美國食品和藥物管理局(FDA)、加拿大衞生部(Health Canada)或其他類似監管機構尚未評估有關裸蓋菇素、裸蓋菇素類似物或其他迷幻化合物或營養產品的聲明。這類產品的療效尚未得到批准的研究證實。不能保證使用裸蓋菇素、裸蓋菇素類似物或其他迷幻化合物或營養食品可以診斷、治療、治癒或預防任何疾病或狀況。需要大力開展科學研究和臨牀試驗。該公司尚未對其建議產品的使用進行臨牀試驗。任何對潛在產品的質量、一致性、有效性和安全性的提及，並不意味着該公司在臨牀試驗中驗證了這一點，也不意味着該公司將完成這類試驗。如果公司不能獲得將其業務商業化所需的批准或研究，可能會對公司的業績和運營產生重大不利影響。
譯文內容由第三人軟體翻譯。